Abeona Therapeutics (ABEO) Rating Reiterated by Maxim Group
Maxim Group reaffirmed their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report published on Wednesday. The firm currently has a $35.00 price objective on the biopharmaceutical company’s stock.
“Abeona announced positive early data for ABO-101 in the first patient treated in the P1/2 trial for Sanfilippo Syndrome Type IIIB. As a reminder, this is the second gene therapy candidate targeting Sanfilippo Syndrome behind ABO-102, which has demonstrated positive data in 8 patients so far with Type IIIA disease. The difference between ABO-101 and ABO-102 is the replaced gene, same targeted pathway.”,” Maxim Group’s analyst wrote.
A number of other research analysts have also commented on the company. HC Wainwright set a $30.00 price objective on Abeona Therapeutics and gave the company a buy rating in a research report on Thursday, January 4th. Zacks Investment Research lowered Abeona Therapeutics from a buy rating to a hold rating in a research report on Thursday, November 23rd. SunTrust Banks started coverage on Abeona Therapeutics in a research report on Wednesday, November 8th. They issued a buy rating and a $26.00 price objective on the stock. Citigroup started coverage on Abeona Therapeutics in a research report on Tuesday, October 10th. They issued a buy rating and a $32.00 price objective on the stock. Finally, Cantor Fitzgerald increased their price objective on Abeona Therapeutics from $21.00 to $34.00 and gave the company an overweight rating in a research report on Wednesday, October 11th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $27.11.
Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. equities research analysts predict that Abeona Therapeutics will post -0.6 EPS for the current year.
Several large investors have recently bought and sold shares of the company. Swiss National Bank bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $794,000. California Public Employees Retirement System bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $557,000. Teacher Retirement System of Texas bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $163,000. SG Americas Securities LLC bought a new position in shares of Abeona Therapeutics in the 4th quarter worth $218,000. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Abeona Therapeutics by 37.1% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 56,352 shares of the biopharmaceutical company’s stock worth $894,000 after purchasing an additional 15,252 shares during the last quarter. Institutional investors and hedge funds own 41.97% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.